Page results
-
Outcome of National Institute for Health and Care Excellence (NICE) Technology Appraisal for Exagamglogene autotemcel (Exa-cel) for treating transfusion- dependent beta thalassaemia [ID4015] in individuals 12 years and over.
-
This page is for patients who have been referred on a suspected cancer pathway.
-
At UCLH we run seasonal COVID-19 vaccination clinics from our Hospital Hub within UCH. Vaccinations are available to members of the eligible public as well as UCLH patients.
-
Short videos on managing cancer pain, cancer-related fatigue and improving sleep
-
Our Getting Ready for Transition (GReaT) to secondary school parent information session will run on Wednesday 29 January 2025.
-
This page offers advice to patients who are feeling sick.
-
Bed availability is a “significant” factor in determining whether or not a patient is admitted to a critical care bed after surgery, questioning whether some are getting the care they need, a new study from researchers at UCL and UCLH has found for the first time.
-
Pfizer Limited, in agreement with the Medicines Healthcare products Regulatory Agency (MHRA), has withdrawn the product, while a review of the benefits and risks is carried out.
-
This page is for patients with obesity who are waiting for scheduled surgery.
-
We’re proud that UCLH is ranked number one of all acute teaching trusts in new national league tables published today.
File results
-
FOI/2022/0169 - Strategic workforce plan for recruitment and retention of Allied Health Professions
-
FOI/2022/0171 - Consultant-led Referral to Treatment (RTT), outpatients and Patient Initiated Follow-up (PIFU)
-
FOI/2022/0172 - Contraceptive pill data
-
FOI/2022/0174 - Clinical systems for bed management, diagnostic reporting, discharge letters, and integration platform systems
-
FOI/2022/0177 - Assessment and treatment unit for mental health and learning disabilities
-
FOI/2022/0186 - Gender neutral toilets at the Trust
-
FOI/2022/0187 - Intra-operative cell salvage procedures
-
FOI/2022/0189 - Drug treatments for Revolade, Nplate, Doptelet, and Tavlesse
-
FOI/2022/0190 - Spend on private healthcare providers for staff
-
FOI/2022/0192 - Drug treatment for Melanoma patients